Sarcopenic obesity as a distinct geriatric syndrome: Implications for screening, risk stratification, and Dual-target care.

Nila Ganamurali, Mohana Priya Devarajan, Sarvesh Sabarathinam

Helix Research Lab, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu 602105, India.Helix Research Lab, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu 602105, India. · pubmed

Paper

Abstract

Sarcopenic obesity (SO) the coexistence of reduced muscle mass and excess adiposity represents a distinct geriatric syndrome rather than a coincidental overlap of two conditions. SO is driven by inflammation, insulin resistance, and myosteatosis, leading to accelerated functional decline, cardiometabolic risk, and higher mortality. Current diagnostic tools relying on BMI or isolated sarcopenia markers fail to capture this entity, delaying intervention. Recognition of SO requires integrated screening methods, novel risk indices, and dual-target therapies balancing fat loss with muscle preservation. Establishing SO as a clinical syndrome is essential for advancing risk stratification, optimizing management, and informing policy.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Sarcopenic obesity is identified as a distinct geriatric syndrome requiring integrated screening and dual-target therapies. The paper addresses a significant aspect of aging by proposing a new framework for understanding and managing a condition that contributes to functional decline and mortality in older adults.

Author of this paper? Send a correction.